Review: could Gleevec cause Nephrolithiasis?


Nephrolithiasis is found among people who take Gleevec, especially for people who are male, 40-49 old , have been taking the drug for < 1 month, also take medication Zometa, and have Chronic myeloid leukaemia . We study 21,823 people who have side effects while taking Gleevec from FDA and social media. Among them, 96 have Nephrolithiasis. Find out below who they are, when they have Nephrolithiasis and more.

You are not alone

Join a support group for people who take Gleevec and have Nephrolithiasis >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myeloid leukaemia. (latest outcomes from Gleevec 22,558 users)


Nephrolithiasis (calculi in the kidneys) has been reported by people with breathing difficulty, pain, weakness, diarrhea, joint pain (latest reports from 16,976 Nephrolithiasis patients).

On Aug, 27, 2016

21,823 people reported to have side effects when taking Gleevec.
Among them, 96 people (0.44%) have Nephrolithiasis

Number of reports submitted per year:

Could Gleevec cause Nephrolithiasis?

Time on Gleevec when people have Nephrolithiasis *:

  • < 1 month: 30 %
  • 1 - 6 months: 30 %
  • 6 - 12 months: 10 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 10 %
  • 5 - 10 years: 10 %
  • 10+ years: 10 %

Gender of people who have Nephrolithiasis when taking Gleevec *:

  • female: 34.04 %
  • male: 65.96 %

Age of people who have Nephrolithiasis when taking Gleevec *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 6.82 %
  • 20-29: 2.27 %
  • 30-39: 11.36 %
  • 40-49: 34.09 %
  • 50-59: 18.18 %
  • 60+: 27.27 %

Top conditions involved for these people *:

  • Chronic Myeloid Leukaemia (38 people)
  • Osteoporosis (10 people)
  • Malignant Soft Tissue Neoplasm (5 people)
  • Gastrointestinal Stromal Tumour (5 people)
  • Diabetes Mellitus (3 people)

Top co-used drugs for these people *:

  • Zometa (17 people)
  • Rocephin (11 people)
  • Compazine (11 people)
  • Aredia (11 people)
  • Interferon (10 people)

* Approximation only. Some reports may have incomplete information.

** Reports from social media are used.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you have Nephrolithiasis when taking Gleevec?

Browse all side effects of Gleevec

a b c d e f g h i j k l m n o p q r s t u v w x y z

Drugs that are associated with Nephrolithiasis


Could your condition cause Nephrolithiasis


Can you answer these questions?

More questions for: Gleevec, Nephrolithiasis

You may be interested in these reviews

More reviews for: Gleevec, Nephrolithiasis

NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.